Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.67 |
| ▸ | RAB9A | P51151 | 6/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.67 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.67 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660014 | 0.83 | MAPT (0.67) | NPC1SMN1; SMN2RAB9AL3MBTL1UBE2T | |
| 2-(Phenoxymethyl)Benzothiazole SCHEMBL2245843 | 0.80 | NPC1 (1.00) | NPC1SMN1; SMN2RAB9AL3MBTL1UBE2T | |
| SCHEMBL10881697 | 0.80 | KMT2A (0.63) | NPC1SMN1; SMN2RAB9AL3MBTL1UBE2T | |
| SCHEMBL244775 | 0.80 | UBE2T (1.00) | NPC1SMN1; SMN2RAB9AL3MBTL1UBE2T | |
| SCHEMBL20511910 | 0.80 | CYP1A2 (0.73) | NPC1SMN1; SMN2RAB9AL3MBTL1UBE2T | |
| SCHEMBL19372016 | 0.79 | UBE2T (0.70) | NPC1SMN1; SMN2RAB9AL3MBTL1UBE2T | |
| SCHEMBL226465 | 0.79 | UBE2T (0.70) | NPC1SMN1; SMN2RAB9AL3MBTL1UBE2T | |
| SCHEMBL13314539 | 0.79 | NPC1 (0.59) | NPC1SMN1; SMN2RAB9AL3MBTL1UBE2T | |
| SCHEMBL324660 | 0.79 | SMN1; SMN2 (0.59) | NPC1SMN1; SMN2RAB9AL3MBTL1UBE2T | |
| SCHEMBL7541252 | 0.79 | NPC1 (0.77) | NPC1SMN1; SMN2RAB9AL3MBTL1UBE2T |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | claimed |
| EP-2227233-B1 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2013-02-13 | — | — | EP | claimed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | claimed |
| EP-2227233-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2010-09-15 | — | — | EP | claimed |
| WO-2009073620-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2019051198-A1 | PRODRUG INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2019-03-14 | — | — | WO | disclosed |
| CN-103145643-B | Aminothiazole compound dehydration and alkylation method | UNIV WENZHOU | 2015-04-15 | — | — | CN | disclosed |
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| CN-103145643-A | Aminothiazole compound dehydration and alkylation method | UNIV WENZHOU | 2013-06-12 | — | — | CN | disclosed |
| EP-2227233-B1 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20070042975-A1 | Novel indolopyrrolocarbazole derivative with antitumor activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1666485-A1 | NOVEL INDOLOPYRROLOCARBAZOLE DERIVATIVE WITH ANTITUMOR ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | NPC1 3462/4885SMN1; SMN2 4672/4885RAB9A 4328/4885 |
| US-20070042975-A1 | Novel indolopyrrolocarbazole derivative with antitumor activity | HK1, G6PD, HK2 | NPC1 2231/4885SMN1; SMN2 4309/4885RAB9A 3792/4885 |
| US-20130289083-A1 | IDO Inhibitors | IDO1, IDO2, INMT | NPC1 3727/4885SMN1; SMN2 4556/4885RAB9A 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.